Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below 200 Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.28 and traded as low as $0.94. Spero Therapeutics shares last traded at $1.03, with a volume of 330,176 shares.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SPRO shares. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research note on Monday, December 2nd. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target for the company. in a research note on Friday, December 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Stock Performance

The stock has a market capitalization of $56.15 million, a price-to-earnings ratio of 14.72 and a beta of 0.59. The business has a 50-day moving average of $1.17 and a 200-day moving average of $1.27.

Institutional Investors Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC boosted its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 40.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,071,860 shares of the company’s stock after purchasing an additional 309,262 shares during the period. Acadian Asset Management LLC owned about 1.99% of Spero Therapeutics worth $1,392,000 at the end of the most recent quarter. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.